Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02303938
Other study ID # NL44024.008.13
Secondary ID
Status Completed
Phase N/A
First received July 15, 2013
Last updated August 3, 2015
Start date August 2013
Est. completion date July 2015

Study information

Verified date August 2015
Source University of Tilburg
Contact n/a
Is FDA regulated No
Health authority Netherlands: Medical Ethics Review Committee (METC)
Study type Interventional

Clinical Trial Summary

The objective of this pilot randomized controlled trial (RCT) is to assess the feasibility and to determine the effect size of an exercise program in improving objective cognitive functioning.


Description:

Clinical stable patients with 1) low grade glioma (LGG) or 2) anaplastic glioma under age 70 will undergo a home-based exercise program (intervention) or will be assigned to the active controle group. Patients in the intervention group will undergo a 6-month home-based exercise intervention. An individual exercise prescription will be based on the patients' level of aerobic fitness (VO2peak) as measured with cardiopulmonary testing (CPET; on a cycle ergometer with ECG and gas exchange measurement) at baseline. Patients will exercise (e.g., running, biking, swimming) three times per week for 6 months. Session duration will vary between 20 minutes and 45 minutes. Patients in the active control group will be advised to walk regularly based on brochures from 30minutenbewegen.nl.

All primary and secondary outcomes will be assessed at baseline (T0; prior to randomization), and at completion of the 6-month exercise intervention (T1), and at a similar time-point for patients in the active control group. These will include indicators of feasibility (accrual, adherence, compliance and attrition), subjective and objective physical fitness measures, neuropsychological performance scores, and self-reported cognitive symptoms and mental wellbeing.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date July 2015
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Grade II and III gliomas

- age < 50 years

- Karnofsky score > or equal 80

- clinically stable for a minimum of 6 months prior to study entry

- no recent anti-tumor treatment

- interested in undergoing a physical exercise program

- mild to moderate neuropsychological impairment based on normative comparison of objective test performance

- relative VO2peak that leaves room for further improvement of cardiorespiratory fitness.

Exclusion Criteria:

- patients with serious orthopedic conditions or motor deficits

- patients with serious cardiovascular, cardiopulmonary and neurological conditions (or risks)

- patients judged to have psychiatric (including alcohol and drug abuse)

- patients with severe cognitive problems

- patients who report to engage in vigorous exercise (=7 METs) for more than 20 minutes on at least 3 days per week on a regular basis will be excluded

For assessment purposes, study participants will need to have basic fluency in the Dutch language.

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment


Intervention

Behavioral:
physical exercise
Patients in the intervention group will undergo a 6-month home-based exercise intervention. Patients will exercise (e.g., running, biking, swimming) three times per week for 6 months. Session duration will vary between 20 minutes and 45 minutes.

Locations

Country Name City State
Netherlands Tilburg University Tilburg Nood-Brabant

Sponsors (1)

Lead Sponsor Collaborator
University of Tilburg

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Patient reported outcome measured with self-reported questionnaires mood, sleep, fatique, quality of life, and depression are measured with self-reported questionaires at baseline and after intervention at 6 months such as Profile of Mood States (POMS) brief, Multidimensional Fatigue Inventory (MFI), Pittsburgh Sleep Inventory, MOS SF-36 Item Health Survey SF-36, and Brain-cancer specific HRQL questionnaire (QLQ-BN20) 6 months after the initial assessment No
Other Subjective cognition measured with Cognitive Functioning Scale (CFS) and Cognitive Failures Questionnaire (CFQ) Subjective cognition is measured with self-reported questionaire at baseline and after intervention at 6 months 6 months after the initial assessment No
Other Mental well-being measured with self-reported questionnaires Mental well-being is measured with specific questionaire at baseline and after intervention at 6 months 6 months after the initial assessment No
Primary cognitive function as measured by neuropsychological tests neuropsychological test battery will be administered to patients at baseline and immediately after the intervention at 6 months 6 months after the initial assessment No
Secondary Objective measures of physical fitness measured by cardiopulmonary exercise test (CPET) Intervention-related improvement of physical fitness will be assessed with a maximum cardiopulmonary exercise test (CPET). VO2 and of course adverse events are recorded immediately after the intervention ended at 6 months 6 months after the initial assessment Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04859725 - HyperSpectral Imaging in Low Grade Glioma N/A
Suspended NCT03717142 - Feasibility of the LUM Imaging System for Detection of Cancer to the Brain N/A
Not yet recruiting NCT05609994 - ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas Phase 1
Enrolling by invitation NCT04063514 - The Use of Focused Ultrasound and DCE K-trans Imaging to Evaluate Permeability of the Blood-Brain Barrier N/A
Active, not recruiting NCT03154801 - Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors (NEUROSEX) N/A
Recruiting NCT02509442 - Measure of the Potential Evoked by Electric Stimulation N/A
Not yet recruiting NCT05555550 - Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG Early Phase 1